### Edgar Filing: BRISTOW MICHAEL R - Form 3

#### **BRISTOW MICHAEL R**

Form 3

February 05, 2009

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

BRISTOW MICHAEL R

(Last)

(First)

(Middle)

(Month/Day/Year)

01/27/2009

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

ARCA biopharma, Inc. [ABIO]

C/O ARCA BIOPHARMA, INC., Â 8001 ARISTA PLACE,

**SUITE 200** 

(Street)

Statement

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

(Check all applicable)

\_X\_ Director 10% Owner \_X\_ Officer Other

(give title below) (specify below) Chief Science and Med. Officer 6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

4. Nature of Indirect Beneficial

BROOMFIELD, COÂ 80021

(City) (State)

1. Title of Security (Instr. 4)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership Form:

Ownership (Instr. 5) Direct (D)

or Indirect (I) (Instr. 5)

Â Common Stock 272,677 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

required to respond unless the form displays a currently valid OMB control number.

SEC 1473 (7-02)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

**Expiration Date** 

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

4. 5. Ownership Conversion or Exercise Form of

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Price of Derivative Security:

(Month/Day/Year)

## Edgar Filing: BRISTOW MICHAEL R - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Option to Purchase Common Stock	(1)	01/03/2010	Common Stock	7,394	\$ 0.06	D	Â
Option to Purchase Common Stock	(2)	01/22/2019	Common Stock	25,047	\$ 5.57	D	Â

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
· · · · · · · · · · · · · · · · · · ·	Director	10% Owner	Officer	Other		
BRISTOW MICHAEL R C/O ARCA BIOPHARMA, INC. 8001 ARISTA PLACE, SUITE 200 BROOMFIELD, CO 80021	ÂX	Â	Chief Science and Med. Officer	Â		

## **Signatures**

\*\*Signature of Reporting Person

Patrick Wheeler, attorney in fact 02/05/2009

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options are exercisable immediately.
- (2) The options vest in equal monthly installments over a four year period from the date of grant

Date

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2